Know Cancer

or
forgot password

Phase II Multidose, Single Arm, Multicenter Clinical Trial of Cisplatin and Gemcitabine in Combination With Recombinant Humanized Anti-p185HER2 Monoclonal Antibody (Herceptin) in Patients Who Have Untreated p185HER2 Overexpressing Advanced Local Stage (Stage IIIb Pleural Effusion Only) and Metastatic (Stage IV) Non-Small Cell Lung Cancer


Phase 2
18 Years
N/A
Not Enrolling
Both
Lung Cancer

Thank you

Trial Information

Phase II Multidose, Single Arm, Multicenter Clinical Trial of Cisplatin and Gemcitabine in Combination With Recombinant Humanized Anti-p185HER2 Monoclonal Antibody (Herceptin) in Patients Who Have Untreated p185HER2 Overexpressing Advanced Local Stage (Stage IIIb Pleural Effusion Only) and Metastatic (Stage IV) Non-Small Cell Lung Cancer


OBJECTIVES: I. Determine the therapeutic efficacy and toxicity of cisplatin, gemcitabine,
and trastuzumab (Herceptin) in patients with untreated p185-HER2 overexpressing stage IIIB
or IV non-small cell lung cancer. II. Determine the pharmacokinetic interactions among these
drugs in these patients. III. Assess the pharmacodynamics of these drugs in these patients.

OUTLINE: This is a multicenter study. Regimen A: Patients receive gemcitabine IV over 30
minutes followed by cisplatin IV over 2 hours on day 1 and trastuzumab (Herceptin) IV over
90 minutes on day 2. Patients receive trastuzumab IV over 90 minutes followed by gemcitabine
IV over 30 minutes on day 8 and trastuzumab IV over 90 minutes on day 15. Patients proceed
to regimen B on day 22 of regimen A. Regimen B: Patients receive trastuzumab IV over 30-90
minutes, gemcitabine IV over 30 minutes, and cisplatin IV over 2 hours on day 1. Patients
receive trastuzumab IV over 30-90 minutes followed by gemcitabine IV over 30 minutes on day
8 and trastuzumab IV over 30-90 minutes on day 15. Treatment repeats every 21 days for up to
5 courses in the absence of disease progression or unacceptable toxicity. Maintenance: After
completion of 6 courses, patients with stable disease or partial response receive
trastuzumab IV over 30-90 minutes weekly until tumor progression.

PROJECTED ACCRUAL: A total of 20-48 patients will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS: Immunohistochemically confirmed p185-HER2 expressing stage IIIB
(pleural effusions only) or IV non-small cell lung cancer Confirmed overexpression at
least: 1+ p185-HER2 (by DAKO Hercep Test) OR 15 ng/mL serum HER2/neu shed antigen (by
Human HER2 Quantitative ELISA) At least 1 site of measurable disease outside of prior
radiation port Brain metastases allowed provided clinical neurologic status is stable and
head CT scan is stable to improved

PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Zubrod 0-2 Life expectancy: More
than 12 weeks Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at least
1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL (transfusion
allowed) Hepatic: Bilirubin less than 1.5 mg/dL SGPT no greater than 1.5 times normal
Renal: Creatinine clearance at least 60 mL/min Cardiovascular: No myocardial infarction
within the past 6 months No unstable angina, uncontrolled congestive heart failure, or
uncontrolled arrhythmia Ejection fraction at least 40% Other: No other malignancy within
the past 5 years No concurrent serious infection, including post-obstructive pneumonia No
more than 10% weight loss in past 3 months Not pregnant or nursing Negative pregnancy test
Fertile patients must use adequate contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
chemotherapy No other concurrent chemotherapy Endocrine therapy: Not specified
Radiotherapy: See Disease Characteristics At least 3 weeks since prior radiotherapy
(including radiotherapy for brain metastases) No concurrent radiotherapy to only site of
measurable disease Surgery: At least 2 weeks since prior major surgery No concurrent
surgery on only site of measurable disease

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Efficacy of Cisplatin, Gemcitabine, + Trastuzumab in Untreated p185-HER2 Overexpressing Stage IIIB or IV Non-small Cell Lung Cancer

Outcome Time Frame:

21 days cycles for 6 courses

Safety Issue:

No

Principal Investigator

Roy S. Herbst, MD, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

M.D. Anderson Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

DM99-015

NCT ID:

NCT00016367

Start Date:

May 2001

Completion Date:

December 2004

Related Keywords:

  • Lung Cancer
  • stage IIIB non-small cell lung cancer
  • stage IV non-small cell lung cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location

University of Texas - MD Anderson Cancer CenterHouston, Texas  77030-4009